HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 80.3%

Neg 0% Neu 0% Pos 80.3%

HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.